Invitation: Join Our Twitter Chat On China Pharma Issues
This article was originally published in PharmAsia News
PharmAsia News will host a Twitter chat on Thursday, September 19 at 3 pm EST to discuss hot topics related to the China pharmaceutical industry. The chat will be hosted on Twitter via @PharmAsiaNews and includes our editors and special guests – please tune in and join the discussion.
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.